Bevacizumab for the Treatment of Glioblastoma
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 m...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publishing
2013-01-01
|
| Serier: | Clinical Medicine Insights: Oncology |
| Online adgang: | https://doi.org/10.4137/CMO.S8503 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|